Cell line · CVCL_0153
Papers58
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 58
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| The role of miR-335-5p in the redifferentiation of BRAF p.V600E thyroid cancers. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of CSE couples with BRAF V600E to fuel thyroid cancer metastatic progression through zinc-dependent activation of the EMT machinery. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sunitinib enhances cuproptosis induced by copper ionophores via ROS-ATF3-SLC31A1 axis in thyroid Carcinoma. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Roundup® Original DI promotes proliferation in papillary thyroid carcinoma cells: a comparative study highlighting cell-type-dependent effects. | Front Endocrinol (Lausanne) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of ATM reverses radioiodine resistance in differentiated thyroid cancer via genotoxic stress amplification. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Investigating the Role of TNFSF12 in Thyroid Cancer Progression via Single-Cell RNA Sequencing and Integrated Multiomics Analyses. | Mediators Inflamm | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bisphenol A Induces DNA Damage and Differential Cytotoxicity in Thyroid Cells: High-Dose Effects Challenge Regulatory Thresholds. | J Appl Toxicol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Clinical Significance for Risk Stratification of Papillary Thyroid Cancer by TUMORFISHER Circulating Tumor Cell Technique. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting EZH2 reverses thyroid cell dedifferentiation and enhances iodide uptake in anaplastic thyroid cancer. | FEBS Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TGF-β1-based restoration of sodium iodide symporter expression in radioiodine-refractory differentiated thyroid cancer via engineered MSCs. | Mol Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Focal adhesion kinase promotes ribosome biogenesis to drive advanced thyroid cancer cell growth and survival. | Front Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Serum small extracellular vesicles-derived BST2 as a biomarker for papillary thyroid microcarcinoma promotes lymph node metastasis. | Cancer Gene Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Anti-Proliferative and Anti-Migratory Activity of Licorice Extract and Glycyrrhetinic Acid on Papillary Thyroid Cancer Cell Cultures. | Int J Mol Sci | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Exploring the Therapeutic Potential of Extracellular Vesicles Derived from Human Immature Dental Pulp Cells on Papillary Thyroid Cancer. | Int J Mol Sci | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. | Cancer Biol Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti-tumor effects. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| First Evidence of Mineralocorticoid Receptor Gene and Protein Expression in Rat and Human Thyroid Tissues and Cell Cultures. | Int J Mol Sci | 2024 | Its Methods give the RRID and name the line | PubMed | |
| TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis. | Sci Adv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2. | Mol Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0153/papers